Table 5.
Comparison of peripheral innate and adaptive immune cells of COVID-19 survived patients with non-survived cases.
| Variables | Survived = 17 n | Non-survived = 12 n | P -value | ||
|---|---|---|---|---|---|
|
Severe = 11n (64.7%) |
Critical = 6n (35.30%) |
Severe = 1n (8.3%) |
Critical = 11n (91.7%) |
||
| Median (IQR) | Mean ± SD | Median (IQR) | Mean ± SD | ||
| Age, years | 60.80 ± 16.42 | 63.39 ± 14.78 | Φ 0.546 | ||
| CD3+ Total T Lymphocyte (%) | 67.18 ± 11.20 | 53.73 ± 11.36 | Φ 0.005** | ||
| CD3+CD4+ T cell (%) | 54.53 ± 12.49 | 61.42 ± 10.88 | Φ 0.135 | ||
| CD3+CD8+ T cell (%) | 37.35 ± 11.94 | 29.83 ± 9.48 | Φ 0.081 | ||
| CD14+ Monocyte (%) | 5.82 ± 2.22 | 4.08 ± 2.81 | Φ 0.073 | ||
| CD16+CD56+ NK cell (%) | 7.29 ± 6.17 | 11.67 ± 9.11 | Φ 0.134 | ||
| CD4+/CD8+ Ratio | 1.10 (0.58) | 2.05 (1.31) | Ω 0.080 | ||
| CD19+ B cell (%) | 10.0 (3) | 11.00 (25) | Ω 0.329 | ||
Data are presented as median (IQR) and mean ± SD.
Ω, Mann–Whitney U; Φ, T-test.
**
p < 0.01.